Atezolizumab (anti-PD-L1)

Catalog No.A2004        Batch: A200407

Print

Technical Data

CAS No. 1380723-44-3
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99%
Protein concentration 6.2mg/ml
Endotoxin Level ＜1EU/mg

Biological Activity

Description Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Targets
hPD-L1 [2]
(Cell-free assay)
0.4 nM(Kd)
In vitro

Treatment with single agent atezolizumab exerted a moderate anti-proliferative effect with ~ 30% cell death across all models.[1]
In vivo

when dual drug–loaded, core-shell nanoparticles (DLTPT) is used in combination with anti PD-L1, the tumor growth is inhibited, which induced immune response against tumor metastasis.[2]

Protocol (Only for Reference)

Cell Assay:

  • A MTT cell proliferation assays in human spheroids (A) or EPCAM+/CD45- cells (b), untreated or treated with selumetinib, atezolizumab, avelumab, or their combinations.
Animal Study:

  • Animal Models: 4T1 tumor–bearing BALB/c mice
    Dosages: 2.5 or 5 mg/kg
    Administration: i.v.
    Reference:[2]

Customer Product Validation

Selleck's Atezolizumab (anti-PD-L1) has been cited by 71 publications

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer [ Nat Commun, 2025, 16(1):2374] PubMed: 40064880
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) [ J Transl Med, 2025, 23(1):2] PubMed: 39748404
NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):132] PubMed: 40029463
Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):143] PubMed: 40056167
PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages [ Sci Rep, 2025, 15(1):2303] PubMed: 39824849
In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy [ Nat Commun, 2024, 15(1):9723] PubMed: 39521768
Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state [ Cell Rep Med, 2024, 5(12):101869] PubMed: 39657666
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation [ J Immunother Cancer, 2024, 12(5)e008669] PubMed: 38702145
Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment [ J Immunother Cancer, 2024, 12(4)e008053] PubMed: 38604809
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC [ Cell Death Dis, 2024, 15(2):175] PubMed: 38413563

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.